Phase I trial of r viscumin (INN: aviscumine) given subcutaneously in patients with advanced cancer: a study of the European Organisation for Research and Treatment of Cancer (EORTC protocol number 13001).

@article{Bergmann2008PhaseIT,
  title={Phase I trial of r viscumin (INN: aviscumine) given subcutaneously in patients with advanced cancer: a study of the European Organisation for Research and Treatment of Cancer (EORTC protocol number 13001).},
  author={Lothar Bergmann and Steiner Aamdal and Sandrine Marr{\'e}aud and Denis Lacombe and Manfred Herold and Takuhiro Yamaguchi and Karin Wilhelm-Ogunbiyi and Hans Lentzen and Heinz Zwierzina},
  journal={European journal of cancer},
  year={2008},
  volume={44 12},
  pages={1657-62}
}
Safety of aviscumine by subcutaneous route was assessed in patients with advanced cancer refractory to chemotherapy. Patients with progressive disease received escalating doses twice weekly. Treatment of the accrued 26 patients (10 colorectal cancer (CRC), 6 soft tissue sarcoma (STS), 5 melanoma (MM), 5 others) was well tolerated without substance-related grade 3 or 4 toxicities. Grade 1/2 toxicities were predominantly injection site reactions. Aviscumine lacked dose-limiting toxicity (DLT) up… CONTINUE READING